Company: DVAX
Filing Date: 2025-04-21
Form Type: DEFC14A
Source: 0001193125-25-087127
Chunk: 13

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-21
Form: DEFC14A
Chunk 13
---
. In particular, Mr. Erkman’s
history with Dynavax as an investor dates back to middle of the HBV-16 trial, giving him a long-term perspective on the

15

history of the company’s lead asset. This history, combined with his experience as an investor in other vaccine-focused companies, gives him a deep understanding of the difficulties and
complexities of vaccine development from technical, regulatory, and commercial perspectives. Furthermore, Mr. Erkman’s long history as a buy-side investor would offer a unique opportunity for other
directors to hear precise and highly informed guidance on how public market investors would interpret and react to disclosures, forecasts, strategies, and expectations issued by the Company.

Jeffrey Farrow, age 63.

Jeffrey
Farrow has served as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. since April 2023. Mr. Farrow also serves as a board member of Clover Biotherapeutics, a position he has held since September 2021.
Mr. Farrow previously served as Chief Financial Officer of Global Blood Therapeutics, Inc., a biopharmaceutical company, from April 2016 until December 2022 when it was acquired by Pfizer. At Global Blood Therapeutics, he was part of the team
responsible for the successful regulatory approval and commercial launch of Oxbryta for the treatment of sickle cell disease. Prior to that, Mr. Farrow served as chief financial officer of ZS Pharma, Inc., a biopharmaceutical company, which was
acquired by AstraZeneca in December 2015. Prior to ZS Pharma, he served as the chief financial officer at Hyperion Therapeutics, Inc., a commercial pharmaceutical company, from July 2010 until May 2015 which was acquired by Horizon Therapeutics in
May 2015. He previously served as vice president of finance at Evotec AG, a drug discovery and development company. Prior to Evotec, Mr. Farrow served as vice president of finance and chief accounting officer at Renovis, Inc., a drug discovery
and development company, which was acquired by Evotec AG. Earlier in his career, Mr. Farrow spent seven years working in the audit practice of KPMG LLP. Mr. Farrow holds a B.A. in business administration with a concentration in corporate
finance from California State University at Fullerton and is a certified public accountant (inactive).

As a chief financial officer in
the pharmaceutical industry for